Isoprenaline | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Isoprenaline | hsa00220 | Arginine biosynthesis | 2.33E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
Isoprenaline | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Isoprenaline | hsa00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 3.01E-02 | 1 | Q14442 | PIGH | More | |
Isoprenaline | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
Isoprenaline | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Isoprenaline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Isoprenaline | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | |
Isoprenaline | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Isoprenaline | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Isoprenaline | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Isoprenaline | hsa02010 | ABC transporters | 3.01E-02 | 1 | P45844 | ABCG1 | More | |
Isoprenaline | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | |
Isoprenaline | hsa03013 | RNA transport | 4.49E-02 | 5 | P62826, Q9UBU9, P63279, P68104, Q14232 | RAN, NXF1, UBE2I, EEF1A1, EIF2B1 | More | |
Isoprenaline | hsa03020 | RNA polymerase | 6.21E-04 | 4 | P30876, P24928, P62487, Q9Y535 | POLR2B, POLR2A, POLR2G, POLR3H | More | |
Isoprenaline | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
Isoprenaline | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04020 | Calcium signaling pathway | 4.83E-02 | 4 | Q08828, P0DP23, P05141, P51828 | ADCY1, CALM1, SLC25A5, ADCY7 | More | |
Isoprenaline | hsa04022 | cGMP-PKG signaling pathway | 1.31E-03 | 7 | P04049, P18848, P31751, Q08828, P51828, P05141, P0DP23 | RAF1, ATF4, AKT2, ADCY1, ADCY7, SLC25A5, CALM1 | More | |
Isoprenaline | hsa04024 | cAMP signaling pathway | 1.09E-02 | 5 | Q08828, P51828, P31751, P0DP23, P04049 | ADCY1, ADCY7, AKT2, CALM1, RAF1 | More | |
Isoprenaline | hsa04060 | Cytokine-cytokine receptor interaction | 8.61E-03 | 9 | P14784, P27930, P14778, Q13651, Q9HBE5, P25024, Q9UBD3, P47992, Q93038 | IL2RB, IL1R2, IL1R1, IL10RA, IL21R, CXCR1, XCL2, XCL1, TNFRSF25 | More | |
Isoprenaline | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.06E-03 | 6 | Q8NHW4, P25024, P47992, Q9UBD3, Q13651, P14784 | CCL4L2, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
Isoprenaline | hsa04062 | Chemokine signaling pathway | 1.66E-03 | 9 | P25024, P47992, Q9UBD3, P07948, P42338, P63218, P50151, P49407, P04049 | CXCR1, XCL1, XCL2, LYN, PIK3CB, GNG5, GNG10, ARRB1, RAF1 | More | |
Isoprenaline | hsa04064 | NF-kappa B signaling pathway | 4.85E-04 | 11 | O00463, P14778, P01584, Q13077, Q16548, Q8WV28, P63279, P24522, Q8NHW4, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TRAF1, BCL2A1, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CYLD | More | |
Isoprenaline | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04070 | Phosphatidylinositol signaling system | 9.86E-03 | 4 | P0DP23, O14986, Q16760, P48426 | CALM1, PIP5K1B, DGKD, PIP4K2A | More | |
Isoprenaline | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
Isoprenaline | hsa04072 | Phospholipase D signaling pathway | 6.61E-04 | 7 | P04049, P31751, O14986, Q15438, Q08828, P51828, Q16760 | RAF1, AKT2, PIP5K1B, PSCD1, ADCY1, ADCY7, DGKD | More | |
Isoprenaline | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Isoprenaline | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
Isoprenaline | hsa04114 | Oocyte meiosis | 1.35E-02 | 5 | P0DP23, Q08828, P51828, Q13362, Q14738 | CALM1, ADCY1, ADCY7, PPP2R5C, PPP2R5D | More | |
Isoprenaline | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Isoprenaline | hsa04140 | Autophagy - animal | 4.41E-03 | 6 | P31751, P04049, Q7L523, O75460, Q96GC9, Q8TEV9 | AKT2, RAF1, RRAGA, ERN1, TMEM49, SMCR8 | More | |
Isoprenaline | hsa04141 | Protein processing in endoplasmic reticulum | 2.82E-04 | 8 | P18848, Q15437, Q15436, Q99941, P11142, P07900, Q9NR31, P14625 | ATF4, SEC23B, SEC23A, CREBL1, HSPA8, HSP90AA1, SAR1A, HSP90B1 | More | |
Isoprenaline | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04151 | PI3K-Akt signaling pathway | 4.12E-04 | 9 | P62753, P27348, P07900, P14625, Q16363, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, HSP90B1, LAMA4, TNXB, CREBL1, ATF4, SGK | More | |
Isoprenaline | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04211 | Longevity regulating pathway | 1.32E-03 | 5 | P31751, Q08828, P51828, Q99941, P18848 | AKT2, ADCY1, ADCY7, CREBL1, ATF4 | More | |
Isoprenaline | hsa04213 | Longevity regulating pathway - multiple species | 4.07E-03 | 5 | P31751, Q9Y4H2, Q08828, P51828, Q13547 | AKT2, IRS2, ADCY1, ADCY7, HDAC1 | More | |
Isoprenaline | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Isoprenaline | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.54E-06 | 11 | P07550, Q08828, P51828, P22694, P31751, Q99941, P18848, Q13362, Q14738, P0DP23, Q13557 | ADRB2, ADCY1, ADCY7, PRKACB, AKT2, CREBL1, ATF4, PPP2R5C, PPP2R5D, CALM1, CAMK2D | More | |
Isoprenaline | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04340 | Hedgehog signaling pathway | 3.01E-02 | 1 | Q9Y496 | KIF3A | More | |
Isoprenaline | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04371 | Apelin signaling pathway | 1.24E-02 | 5 | P31751, P04049, Q08828, P51828, P0DP23 | AKT2, RAF1, ADCY1, ADCY7, CALM1 | More | |
Isoprenaline | hsa04380 | Osteoclast differentiation | 1.88E-02 | 4 | Q9NQC7, P23458, P31751, P01584 | CYLD, JAK1, AKT2, IL1B | More | |
Isoprenaline | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Isoprenaline | hsa04613 | Neutrophil extracellular trap formation | 5.32E-05 | 6 | P04049, P11215, Q13547, P58876, Q16778, O60814 | RAF1, ITGAM, HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
Isoprenaline | hsa04620 | Toll-like receptor signaling pathway | 2.54E-03 | 3 | P01584, P31751, Q8NHW4 | IL1B, AKT2, CCL4L2 | More | |
Isoprenaline | hsa04623 | Cytosolic DNA-sensing pathway | 2.21E-04 | 3 | P01584, Q9Y535, Q8NHW4 | IL1B, POLR3H, CCL4L2 | More | |
Isoprenaline | hsa04625 | C-type lectin receptor signaling pathway | 1.45E-03 | 5 | P04049, P01584, Q9NQC7, P31751, P0DP23 | RAF1, IL1B, CYLD, AKT2, CALM1 | More | |
Isoprenaline | hsa04630 | JAK-STAT signaling pathway | 8.73E-03 | 4 | P31751, P23458, Q13651, P04049 | AKT2, JAK1, IL10RA, RAF1 | More | |
Isoprenaline | hsa04640 | Hematopoietic cell lineage | 2.46E-03 | 8 | P14778, P27930, P25063, P07766, P01732, P01730, P06127, P09564 | IL1R1, IL1R2, CD24, CD3E, CD8A, CD4, CD5, CD7 | More | |
Isoprenaline | hsa04650 | Natural killer cell mediated cytotoxicity | 2.93E-05 | 8 | P01375, P20963, P04049, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
Isoprenaline | hsa04657 | IL-17 signaling pathway | 3.33E-03 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | |
Isoprenaline | hsa04658 | Th1 and Th2 cell differentiation | 3.72E-04 | 7 | Q04759, P07766, P20963, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, LCK, TBX21, IL2RB, RUNX3 | More | |
Isoprenaline | hsa04659 | Th17 cell differentiation | 2.58E-04 | 8 | Q04759, P06239, P14784, P14778, Q9HBE5, Q9UL17, P07766, P20963 | PRKCQ, LCK, IL2RB, IL1R1, IL21R, TBX21, CD3E, CD247 | More | |
Isoprenaline | hsa04660 | T cell receptor signaling pathway | 2.37E-04 | 8 | Q04759, P42338, P07766, P20963, P01732, Q13191, P06239, P04049 | PRKCQ, PIK3CB, CD3E, CD247, CD8A, CBLB, LCK, RAF1 | More | |
Isoprenaline | hsa04662 | B cell receptor signaling pathway | 2.69E-04 | 6 | P42338, P60033, P07948, P21854, Q8N149, P04049 | PIK3CB, CD81, LYN, CD72, LILRA2, RAF1 | More | |
Isoprenaline | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Isoprenaline | hsa04713 | Circadian entrainment | 4.54E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
Isoprenaline | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
Isoprenaline | hsa04720 | Long-term potentiation | 1.06E-02 | 4 | P0DP23, P18848, Q08828, P04049 | CALM1, ATF4, ADCY1, RAF1 | More | |
Isoprenaline | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
Isoprenaline | hsa04725 | Cholinergic synapse | 7.81E-04 | 5 | Q08828, P51828, P18848, Q13557, P31751 | ADCY1, ADCY7, ATF4, CAMK2D, AKT2 | More | |
Isoprenaline | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04728 | Dopaminergic synapse | 1.01E-03 | 7 | P31751, Q99941, P18848, Q13557, Q13362, Q14738, P0DP23 | AKT2, CREBL1, ATF4, CAMK2D, PPP2R5C, PPP2R5D, CALM1 | More | |
Isoprenaline | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
Isoprenaline | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Isoprenaline | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.76E-04 | 8 | P14778, P01584, Q08828, P51828, P42338, P24723, Q04759, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PIK3CB, PRKCH, PRKCQ, CALM1 | More | |
Isoprenaline | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04911 | Insulin secretion | 4.09E-05 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | |
Isoprenaline | hsa04912 | GnRH signaling pathway | 1.65E-04 | 6 | Q08828, P51828, P18848, Q13557, P0DP23, P04049 | ADCY1, ADCY7, ATF4, CAMK2D, CALM1, RAF1 | More | |
Isoprenaline | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Isoprenaline | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04915 | Estrogen signaling pathway | 5.89E-05 | 9 | P04049, Q99941, P18848, Q08828, P51828, P31751, P07900, P11142, P0DP23 | RAF1, CREBL1, ATF4, ADCY1, ADCY7, AKT2, HSP90AA1, HSPA8, CALM1 | More | |
Isoprenaline | hsa04916 | Melanogenesis | 4.54E-03 | 4 | P0DP23, Q08828, P51828, P04049 | CALM1, ADCY1, ADCY7, RAF1 | More | |
Isoprenaline | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | |
Isoprenaline | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04923 | Regulation of lipolysis in adipocytes | 5.15E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Isoprenaline | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
Isoprenaline | hsa04925 | Aldosterone synthesis and secretion | 5.46E-05 | 6 | Q99941, P18848, Q08828, P51828, P0DP23, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, CALM1, CAMK2D | More | |
Isoprenaline | hsa04926 | Relaxin signaling pathway | 4.78E-05 | 9 | P31751, Q99941, P18848, P22694, P14780, Q08828, P51828, P04049, P30679 | AKT2, CREBL1, ATF4, PRKACB, MMP9, ADCY1, ADCY7, RAF1, GNA15 | More | |
Isoprenaline | hsa04927 | Cortisol synthesis and secretion | 1.02E-05 | 5 | Q99941, P18848, Q08828, P51828, P22694 | CREBL1, ATF4, ADCY1, ADCY7, PRKACB | More | |
Isoprenaline | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.95E-03 | 4 | P51828, P04049, Q99941, P18848 | ADCY7, RAF1, CREBL1, ATF4 | More | |
Isoprenaline | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa04932 | Non-alcoholic fatty liver disease | 5.87E-04 | 8 | P31751, P01375, P49841, P18848, P48023, O75460, P01584, O95298 | AKT2, TNF, GSK3B, ATF4, FASLG, ERN1, IL1B, NDUFC2 | More | |
Isoprenaline | hsa04934 | Cushing syndrome | 2.20E-04 | 5 | Q99941, P18848, Q08828, P51828, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, CAMK2D | More | |
Isoprenaline | hsa04935 | Growth hormone synthesis, secretion and action | 3.68E-04 | 6 | Q08828, P51828, P04049, Q99941, P18848, P31751 | ADCY1, ADCY7, RAF1, CREBL1, ATF4, AKT2 | More | |
Isoprenaline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Isoprenaline | hsa04970 | Salivary secretion | 7.22E-04 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | |
Isoprenaline | hsa04971 | Gastric acid secretion | 2.54E-03 | 4 | Q08828, P51828, P15311, P0DP23 | ADCY1, ADCY7, VIL2, CALM1 | More | |
Isoprenaline | hsa04976 | Bile secretion | 1.59E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | |
Isoprenaline | hsa05010 | Alzheimer disease | 4.94E-03 | 9 | O95298, Q00535, O75460, P0DP23, P01584, P18848, P31751, P05141, P28070 | NDUFC2, CDK5, ERN1, CALM1, IL1B, ATF4, AKT2, SLC25A5, PSMB4 | More | |
Isoprenaline | hsa05016 | Huntington disease | 2.24E-02 | 7 | O95298, P24928, P30876, P62487, P05141, O75460, P28070 | NDUFC2, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | |
Isoprenaline | hsa05017 | Spinocerebellar ataxia | 3.94E-02 | 4 | O75460, P31751, P28070, P05141 | ERN1, AKT2, PSMB4, SLC25A5 | More | |
Isoprenaline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.67E-02 | 9 | O95298, Q8TEV9, O75460, P18848, P05141, Q00535, P01584, P0DP23, P28070 | NDUFC2, SMCR8, ERN1, ATF4, SLC25A5, CDK5, IL1B, CALM1, PSMB4 | More | |
Isoprenaline | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
Isoprenaline | hsa05031 | Amphetamine addiction | 8.84E-04 | 5 | Q13557, P22694, Q99941, P18848, Q13547 | CAMK2D, PRKACB, CREBL1, ATF4, HDAC1 | More | |
Isoprenaline | hsa05034 | Alcoholism | 1.49E-04 | 5 | Q13547, P04049, P58876, Q16778, O60814 | HDAC1, RAF1, H2BC5, HIST2H2BE, H2BC12 | More | |
Isoprenaline | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | |
Isoprenaline | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | |
Isoprenaline | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Isoprenaline | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
Isoprenaline | hsa05146 | Amoebiasis | 3.65E-05 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | |
Isoprenaline | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
Isoprenaline | hsa05161 | Hepatitis B | 5.33E-03 | 4 | P04049, Q99941, P18848, P27348 | RAF1, CREBL1, ATF4, YWHAQ | More | |
Isoprenaline | hsa05163 | Human cytomegalovirus infection | 4.86E-05 | 17 | P31751, P04049, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P18848, P04637, O00463 | AKT2, RAF1, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, ATF4, TP53, TRAF5 | More | |
Isoprenaline | hsa05164 | Influenza A | 1.49E-02 | 6 | P31751, P01584, P23458, P05141, P04049, Q9UBU9 | AKT2, IL1B, JAK1, SLC25A5, RAF1, NXF1 | More | |
Isoprenaline | hsa05166 | Human T-cell leukemia virus 1 infection | 3.90E-02 | 7 | P23458, P05141, P62826, Q08828, P51828, P18848, P31751 | JAK1, SLC25A5, RAN, ADCY1, ADCY7, ATF4, AKT2 | More | |
Isoprenaline | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | |
Isoprenaline | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
Isoprenaline | hsa05203 | Viral carcinogenesis | 5.38E-04 | 8 | Q99941, P18848, P27348, Q13547, P61978, P58876, Q16778, O60814 | CREBL1, ATF4, YWHAQ, HDAC1, HNRPK, H2BC5, HIST2H2BE, H2BC12 | More | |
Isoprenaline | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Isoprenaline | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05212 | Pancreatic cancer | 3.52E-03 | 4 | P31751, P04049, Q15311, P23458 | AKT2, RAF1, RALBP1, JAK1 | More | |
Isoprenaline | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05215 | Prostate cancer | 3.72E-03 | 3 | P18848, P14625, P04049 | ATF4, HSP90B1, RAF1 | More | |
Isoprenaline | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05219 | Bladder cancer | 5.65E-03 | 3 | P14780, P04637, P04049 | MMP9, TP53, RAF1 | More | |
Isoprenaline | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05224 | Breast cancer | 1.24E-02 | 5 | P04049, P49841, Q92837, P04637, P24522 | RAF1, GSK3B, FRAT1, TP53, GADD45A | More | |
Isoprenaline | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Isoprenaline | hsa05231 | Choline metabolism in cancer | 5.74E-03 | 4 | P04049, P31751, Q16760, O14986 | RAF1, AKT2, DGKD, PIP5K1B | More | |
Isoprenaline | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.57E-04 | 11 | P42338, O95267, P07766, P20963, P09693, P06239, P04049, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, CD3E, CD247, CD3G, LCK, RAF1, TLR2, PRKCQ, MAPK14, CD4 | More | |
Isoprenaline | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
Isoprenaline | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
Isoprenaline | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Isoprenaline | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
Isoprenaline | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |